Hasil Pencarian  ::  Simpan CSV :: Kembali

"Latar belakang: Systemic Immune-inflammation Index adalah suatu indeks hasil perhitungan antara trombosit (T), neutrofil (N), dan limfosit (L) dengan rumus SII = T × N/L. Retinoblastoma risiko tinggi, diantaranya: Rb bilateral, trilateral, grup D-E pada klasifikasi tumor intraokular berdasarkan International Classification of Retinoblastoma (ICRB), stadium III-IV menurut klasifikasi tumor ekstraokular berdasarkan International Staging System for Retinoblastoma (ISSRB), dan gambaran histologi unfavorable. Tujuan: Mengetahui kemampuan SII sebagai prediktor kesintasan tiga tahun Rb risiko tinggi. Metode: Kohor retrospektif, Agustus – September 2024, di RS Dr. Cipto Mangunkusumo. Hasil: Analisis dilakukan terhadap 157 subjek Rb risiko tinggi antara 2016 – 2024. Titik potong berdasarkan kurva Receiver Operating Characteristic (ROC) dengan nilai maksimal indeks Youden berada pada SII 351,72. Overall survival (OS) dan Event free survival (EFS) Rb risiko tinggi pada 36 bulan, berturut-turut adalah 39,5% (SE±4,5%) dan 38,1% (SE±4,5%). Median OS dan EFS 36 bulan, berturut- turut adalah 17 bulan dan 16 bulan. Nilai SII ≥351,72 memiliki median OS 11 bulan dan adjusted HR (aHR) sebesar 1,98 (p=0,02; IK 95% 1,13 – 3,35). Kesimpulan: SII dapat memprediksi kesintasan Rb risiko tinggi.

---

Background: The Systemic Immune-Inflammation Index (SII) is an index calculated from platelets (T), neutrophils (N), and lymphocytes (L) using the formula SII = T × N/L. High-risk Rb includes bilateral Rb, trilateral Rb, group D-E in the intraocular tumor classification based on the International Classification of Retinoblastoma (ICRB), stage III-IV in the extraocular tumor classification based on the International Staging System for Retinoblastoma (ISSRB), and unfavorable histological features.

Objective: To determine the ability of SII as a predictor of three-year survival in high-risk Rb.

Methods: A retrospective cohort study, from August to September 2024 at Dr. Cipto Mangunkusumo Hospital.

Results: The analysis was conducted on 157 high-risk Rb subjects between 2016 and 2024. The cut-off point based on the Receiver Operating Characteristic (ROC) curve, with the maximum Youden index value, was identified at an SII of 351.72. The overall survival (OS) and event-free survival (EFS) rates at 36 months for high-risk Rb were 39,5% (SE±4,5%) dan 38,1% (SE±4,5%), respectively. The median OS and EFS were 17 months and 16 months, respectively. An SII value ≥351.72 was associated with a median OS of 11 months and adjusted HR (aHR) of 1,98 (p=0,02; 95% CI 1,13 – 3,35).

Conclusion: SII may predict survival in high-risk Rb."

"Tumor sistem saraf pusat (SSP) dapat menurunkan massa otot dan massa bebas lemak akibat defisit neurologis yang terjadi serta efek sistemik karena keganasan. Penurunan massa bebas lemak dan massa otot dengan inflamasi saling memengaruhi serta dikaitkan dengan prognosis yang buruk. Penelitian ini bertujuan untuk mengetahui korelasi indeks massa bebas lemak (FFMI) dengan indeks inflamasi imun sistemik (SII) pada pasien tumor SSP. Studi ini merupakan studi potong lintang pada pasien dewasa dengan diagnosis tumor SSP di RSUPN Dr. Cipto Mangunkusumo. Pengukuran FFMI menggunakan bio impedance analysis (BIA). Nilai SII didapatkan dari hasil pemeriksaan laboratorium darah perifer lengkap. Terdapat 74 pasien tumor SSP dengan mayoritas perempuan (59,5%) dan lokasi tersering adalah tumor di otak (79,7%). Proporsi jenis tumor primer maupun sekunder adalah sama (50%). Median indeks massa tubuh (IMT) yaitu 22,85 kg/m2 (11,99–37,60 kg/m2) dengan kategori IMT terbanyak adalah berat badan normal (33,8%). Rerata FFMI yaitu 16,05±3,12 kg/m2 dengan 51,4% pasien memiliki FFMI yang rendah. Median SII sebesar 1140,9 (103,6–8745,6). Tidak didapatkan korelasi antara FFMI dengan SII pada pasien tumor SSP. Pada analisis tambahan didapatkan korelasi negatif bermakna antara FFMI dengan SII pada wanita (r=- 0,351; p=0,019), sebaliknya pada pria tidak ditemukan adanya korelasi (r=-0,096; p=0,613).

---

Central nervous system (CNS) tumors can reduce muscle mass and fat-free mass due to neurological deficits and systemic effects of malignancy. Decreased fat-free mass and muscle mass with inflammation are mutually influential and associated with poor prognosis. This study aimed to determine the correlation between fat-free mass index (FFMI) and systemic immune inflammation index (SII) in patients with CNS tumors. This is a cross-sectional study of CNS tumors adult patients at Dr. Cipto Mangunkusumo National General Hospital. FFMI measurements were obtained using bioimpedance analysis (BIA). SII values obtained from complete peripheral blood laboratory examination results. There were 74 patients with CNS tumors, with the majority being female (59.5%), and the most common location was brain tumors (79.7%). The proportion of primary and secondary tumor types was equal (50%). The median body mass index (BMI) was 22.85 kg/m2 (11.99– 37.60 kg/m2), with the majority falling under the normal weight category (33.8%). The mean FFMI was 16.05±3.12 kg/m2, with 51.4% of patients having a low FFMI. The median SII was 1140.9 (103.6–8745.6). There was no correlation between FFMI and SII in patients with CNS tumors. In additional analysis, a significant negative correlation was found between FFMI and SII in women (r=-0.351; p=0.019), whereas in men, no correlation was found (r=-0.096; p=0.613)."